Purpose The metabolism of tamoxifen is influenced by various cytochrome p450 enzymes, including CYP2D6 and CYP2C19, leading to variations in the levels of endoxifen, even with the same tamoxifen dose. However, the clinical significance of endoxifen for the prognosis of breast cancer patients remains controversial. This study aimed to elucidate the relevance of endoxifen level to recurrence-free survival censored with tamoxifen discontinuation (RFSt), representing the RFS for tamoxifen itself, of breast cancer patients and determine a suitable cutoff for prognostication.
Materials and Methods The study included 478 breast cancer patients. Tamoxifen and its metabolites, including endoxifen, were measured using liquid chromatography-tandem mass spectrometry. An optimal cutoff was determined with maximally selected rank statistics. Survival analysis and Cox regression were conducted based on this cutoff.
Results An endoxifen level of 21.00 ng/mL was the optimal cutoff for prognostication. Survival analysis revealed a statistically significant difference in RFSt between the low endoxifen group (≤ 21.00 ng/mL) and the high endoxifen group (> 21.00 ng/mL) (log-rank test, p=0.032). The 10-year probability of RFSt was 83.2% (95% confidence interval [CI], 77.0 to 89.9) and 88.3% (95% CI, 83.3 to 93.5) in the low and high endoxifen groups, respectively. Multivariable Cox proportional hazards regression indicated endoxifen concentration as a significant factor associated with prognosis.
Conclusion Endoxifen could serve as a marker for appropriate tamoxifen treatment with a cutoff of 21.00 ng/mL. Based on this cutoff, therapeutic drug monitoring would benefit patients displaying suboptimal endoxifen concentrations.
Purpose We evaluated the association between changes in social support after cancer treatment and recurrence-free survival (RFS) in such patients using a prospective cohort study.
Materials and Methods Data were obtained from a prospective cohort study (NCT03131089) conducted at Samsung Medical Center (2013-2021). The primary outcome measure was RFS. Social support was measured using the social and family well-being (SFWB) domain of the Functional Assessment of Cancer Therapy-General. We calculated the changes in SFWB scores before and during treatment and the hazard ratio for RFS by comparing such changes.
Results The mean±standard deviation (SD) age of the patients was 35±3.9 years, and 71.5% and 64.8% of the patients were married and had children, respectively. The mean±SD SFWB score at baseline was 20.5±5.0 out of 26. After cancer treatment, 35.9%, 10.3%, and 53.8% of the participants had increasing, unchanged, and decreasing SFWB scores, respectively. The decreasing SFWB score group had a higher risk of mortality or recurrence than the increasing group. Risk factors for the decreasing score were the presence of children during diagnosis.
Conclusion In this cohort, changes in social support after treatment were associated with RFS in young patients with breast cancer. Health professionals should develop family interventions to help them receive proper social support.
Haeyoung Kim, Su SSan Kim, Ji Sung Lee, Jae Sun Yoon, Hyun Jo Youn, Hyukjai Shin, Jeong Eon Lee, Se Kyung Lee, Il Yong Chung, So-Youn Jung, Young Jin Choi, Jihyoung Cho, Sang Uk Woo, Korean Breast Cancer Society
Cancer Res Treat. 2023;55(2):580-591. Published online December 27, 2022
Purpose This study aimed to evaluate the incidence and prognosis of second non-breast primary cancer (SNBPC) among Korean survivors of breast cancer.
Materials and Methods Data from the Korean National Health Insurance Service were searched to identify women who received curative surgery for initial breast cancer (IBC) between 2003 and 2008 (n=64,340). Among them, patients with the following characteristics were excluded: other cancer diagnosis before IBC (n=10,866), radiotherapy before IBC (n=349), absence of data on sex or age (n=371), or male (n=248). Accordingly, data of 52,506 women until December 2017 were analyzed. SNBPC was defined as a newly diagnosed SNBPC that occurred 5 years or more after IBC diagnosis.
Results The median follow-up time of all patients was 12.13 years. SNBPC was developed in 3,084 (5.87%) women after a median of 7.61 years following IBC diagnosis. The 10-year incidence of SNBPC was 5.78% (95% confidence interval [CI], 5.56 to 6.00). Higher SNBPC incidence was found in survivors with the following factors: old age at IBC diagnosis, low household income, and receiving combined chemotherapy with endocrine therapy, whereas receiving radiotherapy was related to a lower incidence of SNBPC (hazard ratio, 0.89; p < 0.01). Among the patients with SNBPC, the 5-year survival rate was 62.28% (95% CI, 65.53 to 69.02).
Conclusion Approximately 5% of breast cancer survivors developed SNBPC within 10 years after IBC diagnosis. The risk of SNBPC was associated with patient’s age at IBC diagnosis, income level, and a receipt of systemic treatments.
Citations
Citations to this article as recorded by
Association of radiotherapy for stage I–III breast cancer survivors and second primary malignant cancers: a population-based study Jin Shi, Jian Liu, Guo Tian, Daojuan Li, Di Liang, Jun Wang, Yutong He European Journal of Cancer Prevention.2024; 33(2): 115. CrossRef
Danbee Kang, Ka Ryeong Bae, Yeojin Ahn, Nayeon Kim, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Young Mog Shim, Dong Hyun Sinn, Seung Yeop Oh, Mison Chun, Jaesung Heo, Juhee Cho
Cancer Res Treat. 2023;55(2):419-428. Published online November 8, 2022
Purpose We developed a comprehensive return to work (RTW) intervention covering physical, psycho-social and practical issues for patients newly diagnosed and evaluated its efficacy in terms of RTW.
Materials and Methods A multi-center randomized controlled trial was done to evaluate the efficacy of the intervention conducted at two university-based cancer centers in Korea. The intervention program comprised educational material at diagnosis, a face-to-face educational session at completion of active treatment, and three individualized telephone counseling sessions. The control group received other education at enrollment.
Results At 1-month post-intervention (T2), the intervention group was more likely to be working compared to the control group after controlling working status at diagnosis (65.4% vs. 55.9%, p=0.037). Among patients who did not work at baseline, the intervention group was 1.99-times more likely to be working at T2. The mean of knowledge score was higher in the intervention group compared to the control group (7.4 vs. 6.8, p=0.029). At the 1-year follow-up, the intervention group was 65% (95% confidence interval, 0.78 to 3.48) more likely to have higher odds for having work.
Conclusion The intervention improved work-related knowledge and was effective in facilitating cancer patients’ RTW.
Citations
Citations to this article as recorded by
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin JMIR Research Protocols.2024; 13: e54707. CrossRef
A visualized and bibliometric analysis of cancer vocational rehabilitation research using CiteSpace Zebing Luo, Xuejia Liu, Chujun Chen Work.2024; : 1. CrossRef
Psychosocial Adjustment Experiences Among Nasopharyngeal Carcinoma Survivors Jie Jiang, Ming-Hui Yan, Yu-Ying Fan, Jun-E Zhang Cancer Nursing.2023;[Epub] CrossRef
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1091-1098. Published online January 10, 2022
Purpose Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist.
Materials and Methods We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020.
Results Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%).
Conclusion Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.
Citations
Citations to this article as recorded by
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang World Journal of Surgical Oncology.2024;[Epub] CrossRef
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao The Breast.2024; 75: 103733. CrossRef
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sem Acta Oncologica.2023; 62(4): 381. CrossRef
Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials Faizan Fazal, Muhammad Nauman Bashir, Maham Leeza Adil, Usama Tanveer, Mansoor Ahmed, Taha Zahid Chaudhry, Ali Ahmad Ijaz, Muhammad Haider Cureus.2023;[Epub] CrossRef
Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study Yeon Jin Kim, Hye Jin Kim, Soo Yeon Chung, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jai Min Ryu Annals of Surgical Treatment and Research.2023; 105(1): 10. CrossRef
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence Inês Soares de Pinho, Paulo Luz, Lucy Alves, Raquel Lopes-Brás, Vanessa Patel, Miguel Esperança-Martins, Lisa Gonçalves, Ritas Freitas, Diana Simão, Maria Roldán Galnares, Isabel Fernandes, Silvia Artacho Criado, Salvador Gamez Casado, Jose Baena Cañada, Clinical Drug Investigation.2023; 43(9): 691. CrossRef
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim The Breast.2023; 72: 103594. CrossRef
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, Min Hwan Kim, Jae Ho Jeong, Ji-Yeon Kim, Dae-Won Lee, Jin-Hee Ahn, Heejung Chae, Kyung-Hun Lee, Jee Hyun Kim, Keun Seok Lee, Joo Hyuk Sohn, Yoon-La Choi, Seock-Ah Im, Kyung Hae Jung, Yeon Hee Park JAMA Oncology.2022; 8(9): 1271. CrossRef
Purpose
Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant.
Materials and Methods
This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed.
Results
A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected.
Conclusion
We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.
Citations
Citations to this article as recorded by
Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice Jeanette Yuen, Siqin Zhou, Rebecca Caeser, Mallika Venkatramani, Diana Nur Bte Ishak, Shao-Tzu Li, Zewen Zhang, Jianbang Chiang, Sock Hoai Chan, Joanne Ngeow European Journal of Human Genetics.2025;[Epub] CrossRef
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu Scientific Reports.2024;[Epub] CrossRef
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie Breast Cancer Research and Treatment.2024; 208(1): 155. CrossRef
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim Cancer Genetics.2022; 266-267: 19. CrossRef
Sungkeun Shim, Danbee Kang, Nayeon Kim, Gayeon Han, Jihyun Lim, Hyunsoo Kim, Jeonghyun Park, Mankyung Lee, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Jai Min Ryu, Seok Jin Nam, Se Kyung Lee, Juhee Cho
Cancer Res Treat. 2022;54(3):834-841. Published online October 13, 2021
Purpose Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors.
Materials and Methods We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques.
Results The COST-K demonstrated good internal consistency, with a Cronbach’s α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=–0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, –0.18; constipation, –0.14; diarrhea, –0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity.
Conclusion The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.
Citations
Citations to this article as recorded by
Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy Jeremy P. Harris, Eric Ku, Garrett Harada, Sophie Hsu, Elaine Chiao, Pranathi Rao, Erin Healy, Misako Nagasaka, Jessica Humphreys, Michael A. Hoyt American Journal of Hospice and Palliative Medicine®.2024; 41(6): 592. CrossRef
Financial Toxicity in Radiation Oncology: Impact for Our Patients and for Practicing Radiation Oncologists Victoria S. Wu, Xinglei Shen, Janet de Moor, Fumiko Chino, Jonathan Klein Advances in Radiation Oncology.2024; 9(3): 101419. CrossRef
Measures of financial toxicity in cancer survivors: a systematic review L. B. Thomy, M. Crichton, L. Jones, P. M. Yates, N. H. Hart, L. G. Collins, R. J. Chan Supportive Care in Cancer.2024;[Epub] CrossRef
Validation of the COmprehensive Score for Financial Toxicity (COST) in Vietnamese patients with cancer Binh Thang Tran, Dinh Duong Le, Thanh Gia Nguyen, Minh Tu Nguyen, Minh Hanh Nguyen, Cao Khoa Dang, Dinh Trung Tran, Le An Pham PLOS ONE.2024; 19(6): e0306339. CrossRef
Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis Stevanus Pangestu, Fanni Rencz Value in Health.2023; 26(2): 300. CrossRef
Association between financial toxicity and health-related quality of life of patients with gynecologic cancer Yusuke Kajimoto, Kazunori Honda, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Keiichi Fujiwara, Ataru Igarashi International Journal of Clinical Oncology.2023; 28(3): 454. CrossRef
Financial Toxicity Following Cancer in a Middle-Income Country with a Pluralistic Health System: Validation of the COST Questionnaire Veni V. Sakti, Mahmoud Danaee, Cheng-Har Yip, Ros S. A. Bustamam, Marniza Saad, Gin Gin Gan, Jerome Tan, Yueh Ni Lim, Flora L.T. Chong, Murallitharan Munisamy, Farahida Mohd Farid, Boon Lui Sew, Yek-Ching Kong, Nishalini Muniandy, Nirmala Bhoo-Pathy Cancer Care Research Online.2023; 3(3): e044. CrossRef
Financial Toxicity Among Breast Cancer Patients Yi Kuang, Xiaoyi Yuan, Zheng Zhu, Weijie Xing Cancer Nursing.2023;[Epub] CrossRef
Heterogeneity of financial toxicity and associated risk factors for older cancer survivors in China Mingzhu Su, Siqi Liu, Li Liu, Fang Wang, Jiahui Lao, Xiaojie Sun iScience.2023; 26(10): 107768. CrossRef
Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis Yusuf Çeli̇k, Sevilay Şenol Çeli̇k, Seda Sarıköse, Hande Nur Arslan Supportive Care in Cancer.2023;[Epub] CrossRef
Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer Yusuke Kajimoto, Takashi Shibutani, Shoji Nagao, Satoshi Yamaguchi, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Kazunori Honda, Ataru Igarashi International Journal of Gynecologic Cancer.2022; : ijgc-2022-003410. CrossRef
Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1382-1388. Published online March 11, 2016
Purpose The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.
Citations
Citations to this article as recorded by
HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN Kamal Saeed, Shewaz Salih JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11. CrossRef
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung Breast Cancer Research and Treatment.2021; 187(3): 785. CrossRef
Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh PLOS ONE.2021; 16(12): e0261258. CrossRef
Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer? Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky The American Journal of Surgery.2020; 220(6): 1417. CrossRef
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto Breast Disease.2018; 37(4): 177. CrossRef
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri Journal of Translational Medicine.2018;[Epub] CrossRef
Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei World Journal of Surgical Oncology.2018;[Epub] CrossRef
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey Annals of Surgical Oncology.2017; 24(10): 2881. CrossRef
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei Medicine.2016; 95(44): e5302. CrossRef
Ji-Yeon Kim, Kyunghee Park, Hae Hyun Jung, Eunjin Lee, Eun Yoon Cho, Kwang Hee Lee, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1338-1350. Published online February 18, 2016
Purpose TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
Materials and Methods
We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
Results
Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57,respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patientswith a TP53 missense mutation (5-year distantrecurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
Conclusion
Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.
Citations
Citations to this article as recorded by
Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer Rachel Han, Sharon Nofech-Mozes, Dina Boles, Hannah Wu, Nikolina Curcin, Elzbieta Slodkowska International Journal of Surgical Pathology.2024; 32(2): 239. CrossRef
Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez, Luis G. Gu Medicina.2024; 60(1): 168. CrossRef
TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation Yali Su, Jiaxuan Zhao, Haoran Fu, Zeliang Liu, Panyan Du, Jianxia Zheng, Jinghua Wu, Jinghua Zhang Biochemical Pharmacology.2024; 221: 116047. CrossRef
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo Cancers.2024; 16(6): 1184. CrossRef
Exploration of newly synthesized deferasirox derivatives as potential anti-cancer agents via in-vitro and in-silico approaches Muhammad Zahid Ullah, Zahid Hussain, Syed Ahmad Shakir, Mahnoor Mahmood, Syeda Abida Ejaz, Mubashir Aziz, Ammara Fayyaz, Jamshed Iqbal, Amara Mumtaz International Journal of Biological Macromolecules.2024; 283: 137971. CrossRef
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu Journal of Personalized Medicine.2023; 13(2): 190. CrossRef
The role of p53 and ki67 in predicting clinical outcome in breast cancer patients Bhanu Prakash Lalkota, B.J Srinivasa, Mani V. Swamy, Diganta Hazarika, B.M Jeet, K Jyothi, Mithua Ghosh, Suhail M. Sayeed, Mohammad Nasiruddin, Radheshyam Naik Journal of Cancer Research and Therapeutics.2023; 19(2): 208. CrossRef
Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis Xing Chang, Zi Liu, Simeng Cao, Jiang Bian, Dayong Zheng, Nuo Wang, Qi Guan, Yingliang Wu, Weige Zhang, Zengqiang Li, Daiying Zuo Toxicology and Applied Pharmacology.2022; 436: 115883. CrossRef
Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer Jie Yao, Qian Chen, Jun‐qi Zhu, Rui‐gang Cai The Journal of Gene Medicine.2022;[Epub] CrossRef
Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro Konrad A. Szychowski, Bartosz Skóra, Tadeusz Pomianek Biomedicine & Pharmacotherapy.2022; 151: 113149. CrossRef
p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang Cancer Investigation.2022; 40(10): 879. CrossRef
Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer Hyo-Jin Kim, Bo-Gyeong Seo, Eun-Chan Seo, Kwang-Min Lee, Cheol Hwangbo Current Issues in Molecular Biology.2022; 44(12): 5848. CrossRef
An integrative pan-cancer analysis of COPB1 based on data mining Heyan Chen, Kunlong Li, Yijun Li, Peilin Xie, Jianjun He, Huimin Zhang Cancer Biomarkers.2021; 30(1): 13. CrossRef
Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma Lauren J. Mills, Logan G. Spector, David A. Largaespada, Lindsay A. Williams Biology of Sex Differences.2021;[Epub] CrossRef
GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature Patrizia Querzoli, Massimo Pedriali, Rosa Rinaldi, Paola Secchiero, Paolo Giorgi Rossi, Elisabetta Kuhn Diagnostics.2021; 11(4): 604. CrossRef
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis Dharambir Kashyap, Vivek Kumar Garg, Elise N. Sandberg, Neelam Goel, Anupam Bishayee Pharmaceutics.2021; 13(4): 569. CrossRef
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing Liu, Han Han-Zhang, Analyn Lizaso, Ning Liao Frontiers in Oncology.2021;[Epub] CrossRef
Syndrome de Peutz–Jeghers et surveillance mammaire : les nouvelles recommandations à propos d’une observation M. Osada, P. Maniez, N. Taris, C. Mathelin Gynécologie Obstétrique Fertilité & Sénologie .2021; 49(10): 795. CrossRef
Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer Reyhaneh Farghadani, Rakesh Naidu Cancers.2021; 13(14): 3427. CrossRef
Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases Wachiraphan Supsavhad, Bardes B. Hassan, Jessica K. Simmons, Wessel P. Dirksen, Said M. Elshafae, Nicole A. Kohart, Aylin A. Demirer, Thomas J. Rosol Veterinary Sciences.2021; 8(8): 153. CrossRef
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines Ashkan Shahbandi, Hoang D. Nguyen, James G. Jackson Trends in Cancer.2020; 6(2): 98. CrossRef
The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang Breast Cancer Research and Treatment.2020; 180(1): 237. CrossRef
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu Cancer Communications.2020; 40(6): 260. CrossRef
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer Gu Xiao, Devon Lundine, George K. Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L. Donabedian, Thomas Reiner, Galina F. Khramtsova, Olufunmilayo I. Olopade, Alexander Mazo, Jill Bargonetti Cancer Research.2020; 80(3): 394. CrossRef
Genomic analysis of racial differences in triple negative breast cancer Chang-Sheng Chang, Eiko Kitamura, Joan Johnson, Roni Bollag, Lesleyann Hawthorn Genomics.2019; 111(6): 1529. CrossRef
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy Hyeon Jeong Oh, Jeong Mo Bae, Xianyu Wen, Seorin Jung, Younghoon Kim, Kyung Ju Kim, Nam-Yun Cho, Jung Ho Kim, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang British Journal of Cancer.2019; 120(8): 797. CrossRef
Immunostaining for p53 and p16CDKN2A Protein Is Not Predictive of Prognosis for Dogs with Malignant Mammary Gland Neoplasms John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson Veterinary Sciences.2019; 6(1): 34. CrossRef
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer Paul B. Mullan, Victoria Bingham, Paula Haddock, Gareth W. Irwin, Elaine Kay, Stephen McQuaid, Niamh E. Buckley BMC Cancer.2019;[Epub] CrossRef
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang, Li-hua Zheng, Sonali Jindal, Yun-jiang Liu Medicine.2019; 98(18): e15449. CrossRef
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad PLOS ONE.2019; 14(6): e0218030. CrossRef
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00 Elisabetta Munzone, Kathryn P. Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Aron Goldhirsch, Massimo B Breast Cancer Research and Treatment.2018; 170(2): 351. CrossRef
Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo Liangjian Xiang, Xiaoyu Xu, Shuo Zhang, Dongyan Cai, Xiaofeng Dai Free Radical Biology and Medicine.2018; 124: 205. CrossRef
Genetic Markers in Triple-Negative Breast Cancer Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch Clinical Breast Cancer.2018; 18(5): e841. CrossRef
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy‐treated triple negative breast cancer Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam The Kaohsiung Journal of Medical Sciences.2018; 34(12): 663. CrossRef
Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer Yanli Luo, Wentao Huang, Huizhen Zhang, Guang Liu Oncology Letters.2018;[Epub] CrossRef
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman PLOS ONE.2017; 12(2): e0172324. CrossRef
Alcohol promotes migration and invasion of triple‐negative breast cancer cells through activation of p38 MAPK and JNK Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Xiaohe Yang Molecular Carcinogenesis.2017; 56(3): 849. CrossRef
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis Zongbi Yi, Fei Ma, Chunxiao Li, Rongrong Chen, Lifang Yuan, Xiaoying Sun, Xiuwen Guan, Lixi Li, Binliang Liu, Yanfang Guan, Haili Qian, Binghe Xu Scientific Reports.2017;[Epub] CrossRef
TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas Táya F. Oliveira, Tábata Maués, Mariana S. Ramundo, Agnes Marie S. Figueiredo, Marcela F. V. de Mello, Kênia B. El-Jaick, Maria de Lourdes G. Ferreira, Ana Maria R. Ferreira Journal of Veterinary Diagnostic Investigation.2017; 29(6): 865. CrossRef
Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer Jisela Dimas-González, Vilma Maldonado-Lagunas, José Díaz-Chávez, María Eugenia López-Arellano, José Muñoz-Camacho, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez Oncology Reports.2017; 37(5): 3026. CrossRef
Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing Xi-Xi Chen, Qian Zhong, Yang Liu, Shu-Mei Yan, Zhang-Hua Chen, Shan-Zhao Jin, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai, Mu-Sheng Z Nature Communications.2017;[Epub] CrossRef
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park Oncotarget.2017; 8(17): 27997. CrossRef
miR-34a expression in human breast cancer is associated with drug resistance Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao Oncotarget.2017; 8(63): 106270. CrossRef
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer Min Chong Kim, Jung Eun Choi, Soo Jung Lee, Young Kyung Bae Annals of Surgical Oncology.2016; 23(11): 3524. CrossRef
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway Jingwen Xu, Mengting Han, Jiwei Shen, Qi Guan, Zhaoshi Bai, Binyue Lang, Huijuan Zhang, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu Cancer Letters.2016; 383(1): 9. CrossRef